Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer
This study is a multicenter, dose-escalating phase Ib clinical study to evaluate the safety and tolerability of GB226 in combination with fruquintinib in the treatment of mCRC, evaluate the pharmacokinetic characteristics of GB226 in combined therapy, evaluate immunogenicity of GB226, and explore the antitumor activity of GB226 in combination with fruquintinib in the treatment of mCRC.
Metastatic Colorectal Cancer
DRUG: Geptanolimab Injection|DRUG: Fruquintinib
Adverse Event, Adverse Event, up to 52 weeks|Dose Limited Toxicity,DLT, To evaluate the safety of GB226 as defined by dose limited toxicity in patients with metastatic colorectal cancer., up to 52 weeks|Extended period recommended dose,RDE, To evaluate the safety of GB226 as defined by extended period recommended dose in patients with metastatic colorectal cancer., up to 52 weeks
T max, T max, up to 52 weeks|C max, C max, up to 52 weeks|C ss,min, C ss,min, up to 52 weeks|R C,trough, R C,trough, up to 52 weeks|Objective Response Rate, ORR, To evaluate the efficacy of GB226 as defined by objective response rate in patients with metastatic colorectal cancer., up to 52 weeks|Disease control rate (DCR), To evaluate the efficacy of GB226 as defined by overall response rate, in patients with metastatic colorectal cancer., up to 52 weeks|Duration of response, DOR, To evaluate the duration of response (DOR) of GB242 in patients with metastatic colorectal cancer., up to 52 weeks|Progression-free survival, PFS, To evaluate the efficacy of GB226 as defined by progression-free survival in patients with metastatic colorectal cancer., up to 52 weeks|Overall survival, OS, To evaluate the duration from the first administration to death because of any reason in patients with metastatic colorectal cancer., up to 52 weeks|Antidrug antibody, ADA, Antidrug antibody, ADA, up to 52 weeks
This study is a multicenter, dose-escalating phase Ib clinical study to evaluate the safety and tolerability of GB226 in combination with fruquintinib in the treatment of mCRC, evaluate the pharmacokinetic characteristics of GB226 in combined therapy, evaluate immunogenicity of GB226, and explore the antitumor activity of GB226 in combination with fruquintinib in the treatment of mCRC.